Saturday 17 October 2026
Export AUPH’s income statement to Excel — free account
Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 18.9%, EPS grew 81.3%, free cash flow grew 19.1% and total debt fell 25.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
16.51
0.22
−1.32%
Follow AUPH
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
7.35 | 199.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
8 | 7 | 3 | 4 | 2 | 3 | 4 | 3 | 3 | 3 |
Altman Z-Score |
7.86 | 3.20 | 2.71 | 3.56 | 25.70 | 16.26 | 42.31 | 6.20 | 6.32 | (5.40) |
P/S ratio |
7.57 | 5.46 | 7.13 | 6.29 | 64.88 | 32.69 | 5,926.62 | 1,248.84 | 892.47 | 438.51 |
P/FCF ratio |
15.83 | 29.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.12 |
Altman Z″-Score (non-manufacturers) |
5.27 | 0.79 | (0.13) | 4.43 | 6.77 | 7.68 | 12.02 | (2.68) | 5.29 | (13.12) |
Beneish M-Score |
(0.87) | (2.38) | (1.46) | (1.62) | 15.36 | 136.89 | (2.18) | (2.04) | (2.40) | (2.09) |
P/Operating CF |
46.93 | 42.66 | 87.47 | 80.67 | (114.14) | 511.39 | (74.18) | (42.47) | (41.77) | (17.81) |
P/B ratio |
3.69 | 3.40 | 3.31 | 2.08 | 6.18 | 4.02 | 6.31 | 5.14 | 2.25 | 2.11 |
Price to Tangible BV |
3.71 | 3.44 | 3.36 | 2.11 | 6.29 | 4.11 | 6.50 | 5.78 | 2.46 | 3.72 |
EV/Sales |
6.35 | 4.19 | 5.57 | 3.42 | 54.79 | 24.86 | 4,965.10 | 977.01 | 477.49 | 209.33 |
EV/EBITDA |
13.42 | 94.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
13.25 | 22.18 | (29.19) | (5.77) | (15.85) | (17.84) | (24.83) | (8.76) | (4.85) | (1.94) |
EV/FCF |
13.27 | 22.33 | (28.58) | (5.75) | (15.81) | (16.52) | (24.79) | (8.75) | (4.85) | 2.92 |
Quick Ratio |
4.69 | 4.04 | 4.85 | 8.74 | 11.85 | 12.47 | 27.13 | 17.36 | 21.30 | 5.01 |
Current Ratio |
5.25 | 4.57 | 5.50 | 9.60 | 12.63 | 13.11 | 27.90 | 18.30 | 21.50 | 5.22 |
Net Debt/EBITDA |
(2.58) | (28.81) | 3.84 | 3.48 | 2.59 | 4.08 | 4.09 | 2.30 | 3.79 | 1.84 |
Debt/Assets |
6.96% | 10.63% | 13.77% | 1.13% | 1.11% | 1.29% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.09 | 0.16 | 0.20 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.43 | 0.43 | 0.34 | 0.26 | 0.09 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.47 | 7.72 | 0.43 | 0.74 | 0.87 | 0.68 | 0.72 | 0.80 | 0.58 | 0.80 |
Capex/Depreciation |
(0.01) | (0.01) | (0.06) | (0.11) | (0.11) | (4.07) | (0.09) | (0.05) | (0.02) | 23.73 |
Interest Coverage |
26.43 | (1.87) | (30.02) | (29.80) | (432.52) | (81.66) | (36.58) | (34.19) | (56.57) | (1,140.70) |
| 59.91% | 1.52% | (19.92%) | (24.46%) | (40.81%) | (29.07%) | (42.99%) | (46.08%) | (70.20%) | (83.33%) | |
| 44.11% | 1.05% | (15.31%) | (21.33%) | (35.94%) | (26.06%) | (37.60%) | (38.20%) | (57.36%) | (51.44%) | |
ROIC |
30.35% | (7.28%) | (50.58%) | (330.89%) | (590.76%) | (395.10%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
71.74% | 1.64% | (22.23%) | (27.04%) | (37.93%) | (26.18%) | (29.08%) | (51.04%) | (42.36%) | (69.50%) |
Average Days of Receivables |
53.46 | 56.73 | 50.10 | 36.72 | 123.37 | 5.84 | 422.39 | 171.07 | 95.18 | 181.45 |
Research and Development Expense of Revenue |
11.48% | 8.84% | 28.28% | 33.57% | 112.13% | 100.42% | 16,624.53% | 8,937.80% | 8,117.22% | 8,401.16% |
Selling, General and Administrative Expense of Revenue |
35.96% | 73.16% | 111.12% | 146.51% | 380.52% | 191.51% | 7,024.53% | 2,953.35% | 2,893.78% | 4,031.21% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.09 | 0.07 | 0.27 |
Share Based Compensation of Revenue |
5.19% | 13.44% | 25.82% | 24.10% | 68.51% | 34.83% | 2,331.45% | 1,481.64% | 1,014.83% | 799.42% |
Graham Net Nets |
0.15 | 0.21 | 0.20 | 0.45 | 0.15 | 0.22 | 0.15 | 0.17 | 0.41 | 0.27 |
Graham Number |
14.53 | 1.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
13.61% | 0.50% | (6.18%) | (12.79%) | (6.17%) | (5.98%) | (4.70%) | (11.00%) | (23.71%) | (30.23%) |
Free Cash Flow Yield |
6.32% | 3.43% | (2.73%) | (9.47%) | (5.34%) | (4.60%) | (3.38%) | (8.94%) | (11.04%) | 16.34% |
Revenue per Share |
2.11 | 1.64 | 1.23 | 0.94 | 0.35 | 0.42 | 0.00 | 0.01 | 0.01 | 0.00 |
Operating CF per Share |
1.01 | 0.31 | (0.23) | (0.56) | (1.22) | (0.59) | (0.68) | (0.61) | (0.54) | (0.53) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.05) | 0.00 | 0.00 | 0.00 | 0.88 |
Free Cash Flow per Share |
1.01 | 0.31 | (0.24) | (0.56) | (1.22) | (0.64) | (0.68) | (0.61) | (0.54) | 0.35 |
Cash per Share |
2.96 | 2.51 | 2.45 | 2.74 | 3.60 | 3.36 | 3.29 | 1.48 | 2.26 | 1.12 |
Shareholders Equity per Share |
4.33 | 2.64 | 2.64 | 2.86 | 3.70 | 3.44 | 3.21 | 1.33 | 2.15 | 1.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.33 | 2.64 | 2.64 | 2.86 | 3.70 | 3.44 | 3.21 | 1.33 | 2.15 | 1.02 |
Free Cash Flow |
135.41 | 44.11 | (34.18) | (79.82) | (157.99) | (75.44) | (63.69) | (51.68) | (41.19) | 12.40 |
Working Capital |
398.24 | 348.83 | 347.61 | 396.43 | 472.68 | 387.43 | 303.84 | 125.59 | 167.10 | 33.49 |
Capital Expenditures |
(0.25) | (0.28) | (0.72) | (0.29) | (0.30) | (5.58) | (0.10) | (0.07) | (0.02) | 31.11 |
Net Current Asset Value |
321.71 | 273.43 | 254.69 | 377.11 | 449.05 | 363.52 | 289.44 | 99.56 | 151.15 | 20.37 |
EV/EBIT |
15.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.32 | 0.16 | 0.06 | (179.83) |
Price to Operating Income |
18.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
9.21 | 7.12 | 3.47 | 0.74 | 0.62 | 0.29 | 12.59 | 35.29 | 43.16 | 45.21 |
Cash ROIC |
13.13% | 5.55% | (4.25%) | (9.98%) | (16.61%) | (9.29%) | (10.53%) | (21.68%) | (12.14%) | 16.40% |
Accounts Receivable Turnover |
7.26 | 7.76 | 9.34 | 9.28 | 5.62 | 85.70 | 1.09 | 2.84 | 4.29 | 2.60 |
Accounts Payable Turnover |
7.69 | 5.94 | 0.64 | 0.15 | 0.04 | 0.06 | 0.00 | 0.00 | 0.17 | 0.24 |
Inventory Turnover |
0.77 | 0.72 | 0.44 | 0.26 | 0.07 | 0.08 | — | — | 0.00 | 0.00 |
Average Days of Payables |
37.02 | 67.02 | 111.63 | 2,577.04 | 11,691.71 | 8,384.14 | 0.00 | 0.00 | 2,492.31 | 1,924.15 |
Days of Inventory on Hand |
510.54 | 506.88 | 1,024.34 | 1,595.07 | 6,465.62 | 4,708.87 | — | — | 0.00 | 0.00 |
Average Receivables |
39.00 | 30.32 | 18.79 | 14.45 | 8.11 | 0.58 | 0.29 | 0.16 | 0.10 | 0.07 |
Average Payables |
4.25 | 4.76 | 22.16 | 37.47 | 29.87 | 17.99 | 9.12 | 7.52 | 6.88 | 4.56 |
Average Inventory |
42.46 | 39.47 | 32.23 | 22.04 | 16.63 | 13.09 | — | — | — | — |
Average Assets |
651.12 | 549.35 | 509.46 | 507.11 | 503.51 | 393.98 | 235.08 | 167.86 | 123.42 | 45.28 |
Average Common Equity |
479.40 | 377.72 | 391.69 | 442.26 | 443.42 | 353.18 | 205.59 | 139.16 | 100.85 | 27.96 |
Columns are period end dates